Neuroone Medical Technologies vs Anbio Biotechnology
Neuroone Medical Technologies and Anbio Biotechnology are similar in size: $9.1m and $8.6m of revenue in their latest fiscal years. Neuroone Medical Technologies grew faster (163.5% against 5.6%). Anbio Biotechnology kept more of each dollar of sales as profit: a net margin of 74.1% against -39.6%.
| Latest fiscal year | Neuroone Medical TechnologiesNMTC, 2025 | Anbio BiotechnologyNNNN, 2025 |
|---|---|---|
| Revenue | $9.1m | $8.6m |
| Revenue growth | 163.5% | 5.6% |
| Net income | −$3.6m | $6.4m |
| Operating margin | — | 66.7% |
| Net margin | -39.6% | 74.1% |
| Return on equity | -91.3% | 27.0% |
| Free cash flow | −$2.9m | — |
| Cash | $6.6m | $7.8m |
| Total debt | $0 | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 18 | — |
| Market value | $8.2m | $158m |
| Price vs our value range | — | — |
| Moat score | 21 (Weak) | — |
| Insider trades, 12 months | 2 buys, 6 sales | 0 buys, 0 sales |